A REVIEW ON LIFILEUCEL TUMOR-INFILTRATING LYMPHOCYTE THERAPY FOR ADVANCED MELANOMA

Advanced melanoma remains a major therapeutic challenge despite significant advances in immunotherapy, largely due to resistance to immune checkpoint inhibitors such as anti–programmed death-1 antibodies. Tumour-infiltrating lymphocyte therapy has emerged as a promising adoptive cell-based immunotherapeutic approach that utilizes a patient’s own tumour-reactive immune cells to overcome treatment resistance. Lifileucel, also known as AMTAGVI, is the first FDA-approved autologous tumourinfiltrating lymphocyte therapy for patients with unresectable or metastatic melanoma who have progressed following PD-1 blockade and, when applicable, BRAF and MEK inhibitor therapy. This review summarizes the development, historical evolution, mechanism of action, pharmacodynamics, dosage and administration, safety profile, and clinical efficacy of lifileucel in advanced melanoma.